Jinan Central Hospital, Shandong University, Jinan, Shandong, China.
Department of Oncology, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Cancer Sci. 2022 Jun;113(6):1939-1954. doi: 10.1111/cas.15360. Epub 2022 Apr 28.
Infiltration of immunosuppressive cells in the tumor microenvironment (TME) induced colorectal cancer (CRC) progression and its resistance to immunotherapy. Identification of tumor-specific factors to modulate inhibitory immunocyte infiltration would provide alternative and novel targets for CRC immunotherapy. Immunoglobulin-like transcript (ILT) 5 is a negative regulator of myeloid cell activation. However, its expression and functional role in solid tumors is still unknown. Using human CRC tissues and cell lines, we found that ILT5 was highly expressed in CRC cells compared with normal colorectal epithelial cells. Enriched ILT5 in tumor cells was correlated with advanced tumor stages and poor patient survival. Our subsequent in vitro and in vivo studies revealed that tumor-derived ILT5 inhibited the infiltration of T cells, especially that of CD8 T cells in the TME, creating suppressive T-cell contexture. Furthermore, ILT5 directed M2-like polarization of tumor-associated macrophages (TAMs). Inhibition of tumor-derived ILT5 restored the immunosuppressive T-cell and TAM contexture, and restricted CRC progression. Our findings identified ILT5 expression in solid tumor cells for the first time and raised ILT5 as a potential immunotarget and prognostic predictor in CRC.
肿瘤微环境(TME)中免疫抑制细胞的浸润诱导结直肠癌(CRC)的进展及其对免疫治疗的耐药性。鉴定肿瘤特异性因子来调节抑制性免疫细胞浸润将为 CRC 免疫治疗提供替代和新的靶点。免疫球蛋白样转录物(ILT)5 是髓系细胞激活的负调节剂。然而,其在实体瘤中的表达和功能作用尚不清楚。使用人 CRC 组织和细胞系,我们发现与正常结直肠上皮细胞相比,CRC 细胞中高度表达 ILT5。肿瘤细胞中富集的 ILT5 与晚期肿瘤分期和患者生存不良相关。我们随后的体外和体内研究表明,肿瘤衍生的 ILT5 抑制了 T 细胞,特别是 TME 中 CD8 T 细胞的浸润,形成抑制性 T 细胞结构。此外,ILT5 指导肿瘤相关巨噬细胞(TAM)向 M2 样极化。抑制肿瘤衍生的 ILT5 恢复了抑制性 T 细胞和 TAM 结构,并限制了 CRC 的进展。我们的研究结果首次在实体瘤细胞中鉴定出 ILT5 的表达,并提出 ILT5 作为 CRC 中的潜在免疫治疗靶点和预后预测因子。